Literature DB >> 11456056

MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer.

L Esserman1, E Kaplan, S Partridge, D Tripathy, H Rugo, J Park, S Hwang, H Kuerer, D Sudilovsky, Y Lu, N Hylton.   

Abstract

BACKGROUND: The preferred management for women with stage II or locally advanced breast cancer (LABC) is neoadjuvant chemotherapy. Pathologic response to chemotherapy has been shown to be an excellent predictor of outcome. Surrogates that can predict pathologic response and outcome will fuel future changes in management. Magnetic resonance imaging (MRI) demonstrates that patients with LABC have distinct tumor patterns. We investigated whether or not these patterns predict response to therapy.
METHODS: Thirty-three women who received neoadjuvant doxorubicin and cyclophosphamide chemotherapy for 4 cycles and serial breast MRI scans before and after therapy were evaluated for this study. Response to therapy was measured by change in the longest diameter on the MRI.
RESULTS: Five distinct imaging patterns were identified: circumscribed mass, nodular tissue infiltration diffuse tissue infiltration, patchy enhancement, and septal spread. The likelihood of a partial or complete response as measured by change in longest diameter was 77%, 37.5%, 20%, and 25%, respectively.
CONCLUSIONS: MRI affords three-dimensional characterization of tumors and has revealed distinct patterns of tumor presentation that predict response. A multisite trial is being planned to combine imaging and genetic information in an effort to better understand and predict response and, ultimately, to tailor therapy and direct the use of novel agents.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11456056     DOI: 10.1007/s10434-001-0549-8

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  32 in total

1.  Neoadjuvant chemotherapy for breast cancer: correlation between the baseline MR imaging findings and responses to therapy.

Authors:  Takayoshi Uematsu; Masako Kasami; Sachiko Yuen
Journal:  Eur Radiol       Date:  2010-05-09       Impact factor: 5.315

2.  Baseline tumor oxygen saturation correlates with a pathologic complete response in breast cancer patients undergoing neoadjuvant chemotherapy.

Authors:  Shigeto Ueda; Darren Roblyer; Albert Cerussi; Amanda Durkin; Anais Leproux; Ylenia Santoro; Shanshan Xu; Thomas D O'Sullivan; David Hsiang; Rita Mehta; John Butler; Bruce J Tromberg
Journal:  Cancer Res       Date:  2012-07-09       Impact factor: 12.701

3.  Diffuse optical spectroscopic imaging correlates with final pathological response in breast cancer neoadjuvant chemotherapy.

Authors:  Albert E Cerussi; Vaya W Tanamai; David Hsiang; John Butler; Rita S Mehta; Bruce J Tromberg
Journal:  Philos Trans A Math Phys Eng Sci       Date:  2011-11-28       Impact factor: 4.226

4.  Dynamic contrast-enhanced MRI and sonography in patients receiving primary chemotherapy for breast cancer.

Authors:  Filippo Montemurro; Laura Martincich; Giovanni De Rosa; Stefano Cirillo; Vincenzo Marra; Nicoletta Biglia; Marco Gatti; Piero Sismondi; Massimo Aglietta; Daniele Regge
Journal:  Eur Radiol       Date:  2005-01-27       Impact factor: 5.315

Review 5.  Advances in breast imaging: magnetic resonance imaging.

Authors:  Lia Bartella; Elizabeth A Morris
Journal:  Curr Oncol Rep       Date:  2006-01       Impact factor: 5.075

Review 6.  Neoadjuvant therapy for breast cancer: assessing treatment progress and managing poor responders.

Authors:  Robert Wesolowski; Georg Thomas Budd
Journal:  Curr Oncol Rep       Date:  2009-01       Impact factor: 5.075

7.  Integration of microwave tomography with magnetic resonance for improved breast imaging.

Authors:  Paul M Meaney; Amir H Golnabi; Neil R Epstein; Shireen D Geimer; Margaret W Fanning; John B Weaver; Keith D Paulsen
Journal:  Med Phys       Date:  2013-10       Impact factor: 4.071

8.  Predicting pathologic response to neoadjuvant chemotherapy in breast cancer by using MR imaging and quantitative 1H MR spectroscopy.

Authors:  Hyeon-Man Baek; Jeon-Hor Chen; Ke Nie; Hon J Yu; Shadfar Bahri; Rita S Mehta; Orhan Nalcioglu; Min-Ying Su
Journal:  Radiology       Date:  2009-03-10       Impact factor: 11.105

9.  Pretreatment prediction of brain tumors' response to radiation therapy using high b-value diffusion-weighted MRI.

Authors:  Yael Mardor; Yiftach Roth; Aharon Ochershvilli; Roberto Spiegelmann; Thomas Tichler; Dianne Daniels; Stephan E Maier; Ouzi Nissim; Zvi Ram; Jacob Baram; Arie Orenstein; Raphael Pfeffer
Journal:  Neoplasia       Date:  2004 Mar-Apr       Impact factor: 5.715

10.  Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer.

Authors:  Lisa K Dunnwald; Julie R Gralow; Georgiana K Ellis; Robert B Livingston; Hannah M Linden; Jennifer M Specht; Robert K Doot; Thomas J Lawton; William E Barlow; Brenda F Kurland; Erin K Schubert; David A Mankoff
Journal:  J Clin Oncol       Date:  2008-07-14       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.